Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 14Terminated 4Active not recruiting 2

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Recurrence 1Prostatic Neoplasms 1Neoplasms 1Intestinal Obstruction 1Diarrhea 1Breast Neoplasms 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Has results × Octreotide × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

NCT04027348 2022-11-29

Palliative Management of Inoperable Malignant Bowel Obstruction

Roswell Park Cancer Institute

Phase 2 Terminated
15 enrolled 10 charts

Intestinal Obstruction

NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Novartis

Phase 2 Terminated
62 enrolled 25 charts
Breast

Breast Neoplasms, Diarrhea, Neoplasms

NCT00510224 2013-12-11

Sandostatin for Patients With Androgen Independent Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
13 enrolled 4 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡